These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 17623797)

  • 1. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
    Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
    J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
    Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
    El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
    Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of nuclear texture, histone acetylation, and MDR1 gene expression in human drug-sensitive and -resistant OV1 cell lines.
    Yatouji S; El-Khoury V; Trentesaux C; Trussardi-Regnier A; Benabid R; Bontems F; Dufer J
    Int J Oncol; 2007 Apr; 30(4):1003-9. PubMed ID: 17332941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile.
    Yamada H; Arakawa Y; Saito S; Agawa M; Kano Y; Horiguchi-Yamada J
    Leuk Res; 2006 Jun; 30(6):723-34. PubMed ID: 16260035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
    Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
    Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region.
    Flahaut M; Mühlethaler-Mottet A; Martinet D; Fattet S; Bourloud KB; Auderset K; Meier R; Schmutz NB; Delattre O; Joseph JM; Gross N
    Genes Chromosomes Cancer; 2006 May; 45(5):495-508. PubMed ID: 16450357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
    Matsubara H; Watanabe M; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Kamitsuji Y; Watanabe K; Nishijo K; Toguchida J; Nakahata T; Adachi S
    J Pharmacol Exp Ther; 2009 Mar; 328(3):839-48. PubMed ID: 19073909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
    Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
    Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
    Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
    Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
    El-Khoury V; Breuzard G; Fourré N; Dufer J
    Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1.
    Chu F; Chou PM; Zheng X; Mirkin BL; Rebbaa A
    Cancer Res; 2005 Nov; 65(22):10183-7. PubMed ID: 16288004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
    Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.